Inside Medikabazaar’s crisis: A whistleblower, missing millions, and angry investors


AI Summary Hide AI Generated Summary

Key Events

A whistleblower complaint in December 2023 triggered a crisis at Medikabazaar, a B2B medical supply platform in India. The complaint alleged widespread financial fraud, including inflated revenues, unverified inventory, and false transactions.

Forensic audits have validated these allegations. PwC, the company's auditor, resigned and filed a fraud report with the Ministry of Corporate Affairs (MCA).

Series C investors, including Creagis, CDC Group, HealthQuad, and Ackermans & van Haaren, initiated a Rs 279 crore indemnity claim due to alleged misstatements during fundraising.

Impact

The crisis has resulted in a significant leadership change at Medikabazaar. The company is attempting a turnaround, but faces considerable financial pressure and ongoing forensic clean-up efforts. The events raise questions about the company's future and the oversight of investments in the Indian healthtech sector.

  • Inflated revenue figures.
  • Unverified inventory and assets.
  • False transactions.
  • Rs 279 crore indemnity claim from investors.
  • PwC resignation and fraud report to the MCA.

The Fall

Despite publicly announcing plans to raise $200 million in 2024, Medikabazaar was grappling with internal issues. The company, valued at $700 million, served 20,000 pincodes through its platform, Vizi, offering procurement, financing, and logistics services.

Sign in to unlock more AI features Sign in with Google
We located an Open Access version of this article, legally shared by the author or publisher. Open It
  • A whistleblower complaint in December 2023 uncovered widespread financial fraud at Medikabazaar
  • FY23 statements have since been restated to correct inflated revenues, unverified inventory, and false transactions
  • PwC resigned as auditor after flagging unverifiable inventory and assets, and filing a fraud report with the MCA
  • Series C investors have triggered a Rs 279 crore indemnity claim, alleging fundraising misstatements
  • New leadership is attempting a turnaround amid forensic clean-ups and capital pressure

Medikabazaar, the B2B medical supply platform once hailed as a future unicorn in India’s healthtech space, has hurtled from crisis to crisis since a whistleblower complaint in December 2023 accused the then-senior management of fraud. In the 15 months since, the allegations have been validated by forensic audits, its statutory auditor has resigned, and the company has undergone a significant leadership overhaul.

And yet, the company’s troubles are far from over. While Medikabazaar attempts a turnaround, its Series C investors—including Creagis, CDC Group (now BII), HealthQuad, and Ackermans & van Haaren—have activated a Rs 279 crore indemnity claim, demanding accountability for misstatements made during fundraising.

This follows a special notice issued in January by a group of shareholders representing 47.1% of the equity, citing alleged fraud and breach of fiduciary duty. The letter, sourced by The CapTable, was sent by a group of investors, including Arun Venkatachalam, Sunil Kalra, representatives of Rebright Partners, HealthQuad, KOIS Holding, Ackerman & Van Haaren, and others.  

How did a company once valued at $700 million and seen as the “Amazon for hospitals” end up here?

The fall & the fallout

In September 2023, when Medikabazaar disclosed to the media its plans to raise $200 million in equity the following year, there was little sign of the storm brewing inside the company. Everything was seemingly hunky-dory. Medikabazaar, started in 2015, was serving 20,000 pincodes through its digital procurement platform, Vizi, and had a presence in financing, asset lifecycle management, logistics, and procurement services. 

🧠 Pro Tip

Skip the extension — just come straight here.

We’ve built a fast, permanent tool you can bookmark and use anytime.

Go To Paywall Unblock Tool
Sign up for a free account and get the following:
  • Save articles and sync them across your devices
  • Get a digest of the latest premium articles in your inbox twice a week, personalized to you (Coming soon).
  • Get access to our AI features

  • Save articles to reading lists
    and access them on any device
    If you found this app useful,
    Please consider supporting us.
    Thank you!

    Save articles to reading lists
    and access them on any device
    If you found this app useful,
    Please consider supporting us.
    Thank you!